Glytec and ThunderCat Technology Partner to Improve Glycemic Management at VA Hospitals Collaboration Seeks to Improve Outcomes and Reduce Cost of Care for the 25% of Veterans with Diabetes WALTHAM, MASS. (July 7, 2020) – Glytec, the only provider of insulin management software across the continuum of care, and ThunderCat Technology, a Service-Disabled Veteran-Owned Small Business (SDVOSB) that delivers technology …
Glytec’s Glucommander Software Combined with Continuous Glucose Monitoring Enables Patients with Diabetes to Improve Time in Range by More than 25% in Only Four Weeks First study to utilize CGM data with FDA-cleared, cloud-based titration software suggests significantly improved outcomes for patients while optimizing clinical resources WALTHAM, MASS. (June 16, 2020) – Glytec, the only provider of insulin management software across …
Healthcare Providers Showcase Value of Glytec’s Insulin Management Software During Diabetes Technology Society’s Virtual Hospital Poster Session Event Includes Six Studies on Quality and Cost Improvements Achieved Through Glytec eGMS® WALTHAM, MASS. (June 11, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that healthcare providers from five separate health systems will present studies …
Healthcare Providers Share Results of Computer-Guided Insulin Dosing through Glytec During Diabetes Technology Society’s Virtual Hospital Meeting AdventHealth and CHI Franciscan Lead Three-Part Session with Data on Quality and Cost Improvements Achieved Through Electronic Glucose Management WALTHAM, Mass. (April 22, 2020) – Glytec, the only provider of insulin management software across the continuum of care, announced today that AdventHealth and …
COVID-19 Study Shows More than 4 Times In-Hospital Mortality Rate and Increased Length of Stay for Patients with Diabetes and Hyperglycemia Glytec Research Reveals New Insights Into Important Risk Factors for the Large Population of COVID-19 Patients with Glycemic Control Issues WALTHAM, MASS. (April 17, 2020) – Glytec, the only provider of insulin management software across the continuum of care, …
Dr. Bruce Bode Looks Back and Forward at Automated Glucose Control Systems in Hospital Settings at ATTD20 Close Concerns and diaTribe covered Glytec co-founder Dr. Bruce Bode’s presentation ATTD 2020 (Advanced Technologies & Treatments for Diabetes) as he explored the past, present and future of automated glucose control systems in hospital settings Dr. Bruce Bode summarized decades of experience in …
AdventHealth Waterman and Sentara Virginia Beach General Hospital showcased reductions in hypoglycemia and glycemic practice variation utilizing Glytec’s comprehensive systems approach to glucose management.
In partnership with clinical leaders from AdventHealth Waterman and Sentara Virginia Beach General Hospital, Glytec presented two storyboards at the IHI National Forum revealing significant quality and safety improvements for hospitalized patients receiving insulin therapy. On average, this population represents as many as one of every three patients admitted to a general ward and one of every two patients admitted to an intensive care unit. Both hospitals credit their collaboration with Glytec, including utilization of the company’s FDA-cleared decision support platform, eGlycemic Management System® (eGMS®), as well as the company’s highly-tailored quality improvement services.
Glytec, the pioneer of digital therapeutics, has hired an expert team of clinicians to help clients drive and sustain full adoption of best practices in glycemic management.
Hospitals and health systems looking to establish brand dominance, competitive distinction and clinical excellence in diabetes care can turn to a team of experts at Glytec dedicated to helping facilitate full adoption of best practices.
Georgia’s largest health system is heightening the safety and efficacy of insulin therapy across its network of hospitals.
Known nationally for innovative care models, WellStar Health System, in partnership with Glytec, is taking proactive measures to optimize glycemic management for hospitalized patients. The not-for-profit health system is expanding use of Glytec’s patented and FDA-cleared eGlycemic Management System® (eGMS®) beyond its two largest facilities, WellStar Kennestone Hospital and WellStar Atlanta Medical Center, to an additional eight facilities in the Greater Atlanta and surrounding area.
Results of a study by Drs. Guillermo Umpierrez and Jordan Messler observed markedly lower rates of hypoglycemia and hyperglycemia among critical care patients managed with Glytec’s eGlycemic Management System® versus usual care.
Delivering the highest quality care in accordance with best practice is a fundamental tenet of diabetes and glycemic management at Grady Hospital of Atlanta, Georgia, which is why in 2016, the academic medical center chose to standardize its approach and elevate both safety and efficacy by implementing Glytec’s eGlycemic Management System® (eGMS®) in its intensive care and step-down units. A retrospective analysis conducted by Drs. Guillermo Umpierrez and Jordan Messler, and presented at the American Diabetes Association 79th Scientific Sessions, observed that outcomes of patients managed with eGMS® were consistently superior to those managed with a standard protocol. Outcomes measured over a two-year period (December 2016 to December 2018) included incidence of hypoglycemia, incidence of hyperglycemia, target glucose attainment, and reduction in admission-to-discharge blood glucose.
A presentation at ATTD 2019 by renowned diabetologist and researcher, Dr. Bruce Bode, showcased superior clinical and financial outcomes with Glytec’s eGlycemic Management System® versus usual care across multiple studies.
In conclusion to his plenary session at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019), Dr. Bruce Bode delivered a call-to-action to an audience of his peers, espousing they do what is necessary to normalize glucose for all hospitalized patients (emphasis on ALL). He stressed that rates of hypoglycemia remain unacceptably high and use of sliding scale insulin continues to be prevalent despite abundant evidence denouncing it as unsafe and lacking efficacy. “Patients deserve better,” said Bode. With a clear focus on the solution to a decades-long problem of poor glucose control in hospitals, Bode described in detail the advantages of computerized decision support, highlighting data from multiple studies of Glytec’s FDA-cleared eGlycemic Management System® (eGMS®) that demonstrate consistently superior outcomes versus usual care, including significant reductions in hypoglycemia, 30-day readmissions and lengths of stay.
A diabetes webinar hosted by the American Hospital Association and sponsored by Glytec showcased why hypoglycemia prevention is imperative to the safety of patients and to the economics of healthcare delivery.
Featured speakers, Dr. Richard Pratley of Florida Hospital System and Dr. Steven Edelman of UC San Diego Health, recently delivered a unified message to several hundred senior healthcare professionals attending an American Hospital Association webinar: Hypoglycemia [low blood sugar] in the hospital is a major patient safety risk with significant clinical and financial implications. A case study presented by Pratley further revealed that insulin-managed patients who experience severe hypoglycemia, or blood sugar less than 40 mg/dL, have longer stays, higher readmission and mortality rates, and an overall cost of care $10,405 greater than patients whose blood sugar remains in the normal range.
The December 13, 2018 webinar is open to hospital and health system personnel nationwide and will feature Dr. Richard E. Pratley of Florida Hospital System and Dr. Steven V. Edelman of UC San Diego Health.
The population of hospitalized patients with diabetes is on the rise, as is the cost and intensity of their care. Glytec is partnering with the American Hospital Association to deliver a webinar that brings greater attention and awareness to reducing risks and improving safety for patients with diabetes.
Presented at the 18th Annual Diabetes Technology Meeting, the study found that patients treated using Glytec’s solution had 73.2% less hypoglycemia and no bounce backs once transferred from a CCU to a general ward.
With a shifting reimbursement landscape and acuity on the rise for hospitalized patients, the need to minimize length of stay and increase throughput in critical care units is a priority for health systems nationwide. A study conducted by Riverside Medical Center of Kankakee, Illinois, the flagship facility of Riverside Healthcare and the area’s only Magnet® recognized institution, found that by using Glytec’s eGlycemic Management System® (eGMS®), patients admitted to critical care units were transferred to general wards .25 days sooner and there were no “bounce backs,” or returns from general wards to critical care units. The study, presented at the 18th Annual Diabetes Technology Meeting, also found that severe hypoglycemia among patients in critical care units was 73.2% lower when using eGMS®.
Furlong joins the company during a period of extraordinary growth and will assume a key leadership role in scaling commercial operations to meet evolving customer needs.
Glytec, the pioneer of personalized digital therapeutics, is pleased to announce the appointment of Ed Furlong as Chief Operating Officer. “We are thrilled to welcome Ed Furlong to our executive team,” says Glytec’s President and CEO, Bob Leonard. “Ed’s background in helping companies expand and diversify while sustaining strong financial health is ideally suited to our strategic imperatives, especially at this crucial juncture when demand for our products and services is increasing exponentially.”
New study in which insulin dosing was guided by Glytec’s Glucommander™ Outpatient observed markedly greater reductions in A1c among patients who tested blood glucose twice a day or more.
A retrospective study being presented at the 11th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) observed that use of Glytec’s Glucommander™ Outpatient for insulin therapy management combined with blood glucose self-testing at least twice a day resulted in better patient outcomes, including a 3.0% absolute reduction in A1c and virtually no hypoglycemia (0.003%) less than 54 mg/dL.
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
According to new data from a quality improvement study, patients with diabetes experienced no diabetes-related readmissions, urgent care visits, or emergency department visits within 30 days of hospital discharge when their healthcare providers used Glytec’s eGlycemic Management System to guide insulin regimens prescribed at discharge.
Researchers at Eastern Virginia Medical School conducted the study and presented their findings earlier this month at the 17th Annual Diabetes Technology Meeting in Bethesda, Maryland.
New data presented at the 17th Annual Diabetes Technology Meeting observed no diabetes-related readmissions, urgent care visits or emergency department visits within 30 days of hospital discharge when using Glytec’s software.
A prospective quality improvement study led by Eastern Virginia Medical School and presented at the 17th Annual Diabetes Technology Meeting highlights the importance of properly managing transitions of care for patients with diabetes. The study observed that when providers used the Hospital-to-Home (H2H®) module of Glytec’s eGlycemic Management System® to guide insulin regimens prescribed at discharge, patients had no diabetes-related readmissions, urgent care visits or emergency department visits within the first 30 days.
The growing importance of quality ratings will put pressure on hospitals to meet ADA standards for insulin therapy without added manpower.
This June, Glytec came to the American Diabetes Association (ADA) Scientific Sessions with a new story to tell. In years past, Glytec came to ADA armed with data showing that eGMS, a cloud-based glycemic management decision support system, offered a superior way for hospitals to manage insulin therapy for patients. Company officials brought a new focus to the 77th Scientific Sessions in San Diego, California, saying that it’s not enough to offer better time in range. Glytec wants to show how its results translate into what matters most to payers – and a hospital’s bottom line.